<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487082</url>
  </required_header>
  <id_info>
    <org_study_id>65708</org_study_id>
    <nct_id>NCT02487082</nct_id>
  </id_info>
  <brief_title>Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders</brief_title>
  <official_title>Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Institute of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the combined effect of melatonin and donepezil on
      improving sleep and behavior in children with Autism Spectrum Disorders. Melatonin is a
      natural neurohormone that helps regulate sleep and wake cycles. Donepezil is used to improve
      mental function for people with Alzheimer's disease. Children with Autism Spectrum Disorders
      are more likely to have problems sleeping than other children. This difficulty has been
      linked to daytime behavioral problems and family stress.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lethargy/Social Withdrawal</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by subscale of the Aberrant Behavior Checklist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stereotypic Behavior</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by subscale of the Aberrant Behavior Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Children's Sleep Habits Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global improvement</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Clinical Global Impressions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Global improvement</measure>
    <time_frame>Every 5 weeks for a total of 5 times</time_frame>
    <description>Measured by the Parent Reported Global Impressions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin and Donepezil</intervention_name>
    <description>The duration depends on group assignment.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The duration depends on group assignment.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both male and female children

          -  Ages 4 to 17 1/2 years

          -  Diagnosis with Autism Spectrum Disorder on the basis of the clinical judgment of an
             autism specialist, preferably using the Autism Diagnostic Observation Schedule or the
             Autism Diagnostic Interview-Revised.

        Exclusion Criteria:

          -  Abnormal electroencephalogram in the past month

          -  Cardiovascular problems

          -  Asthma

          -  Respiratory disease

          -  Peptic ulcer disease

          -  Renal or hepatic dysfunction (abnormal blood urea nitrogen/creatinine or 2 times
             elevated liver transaminases)

          -  Urinary tract obstruction

          -  Underweight (body mass index &lt; 5th percentile compared to age and sex matched
             population)

          -  Other serious illness

          -  Use of any of the following drugs that might interact with study medications
             (anticholinergics, systemic corticosteroids, phenobarbital, peginterferon,
             beta-blockers or any drug that may cause arrhythmias). Drugs that induce or inhibit
             cytochrome P450 2D6 and cytochrome P450 3A4 (enzymes important for drug metabolism)
             will be allowed because any effects of such medications are likely to be lost in
             individual variability due to genetic polymorphisms.

          -  Use of medications affecting sleep (including melatonin or donepezil). Children on
             these will have to discontinue them for 4 weeks before enrollment in the trial in
             order to establish an appropriate behavioral baseline, and agree to discontinue use
             for the duration of the trial.

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Miller-Horn, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Miller-Horn, MD, MS</last_name>
    <phone>631-444-2599</phone>
    <email>Jill.Miller-Horn@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angie Wong, MHS</last_name>
    <phone>631-444-9083</phone>
    <email>angie.wong@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Wong, MHS</last_name>
      <phone>631-444-9083</phone>
      <email>angie.wong@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Miller-Horn, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Jill Miller-Horn</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Children</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Sleep disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

